Phase II, multicenter, open-label, randomized study of YM155 plus docetaxel as first-line treatment in patients with HER2-negative metastatic breast cancer

Por Clemens, Michael R., Gladkov, Oleg A., Gartner, Elaina, Vladimirov, Vladimir, Crown, John, Steinberg, Joyce, Jie, Fei, Keating, Anne
Publicado no Breast Cancer Res Treat (2014)

Impact of SPARC expression on outcome in patients with advanced pancreatic cancer not receiving nab-paclitaxel: a pooled analysis from prospective clinical and translational trials

Por Ormanns, Steffen, Haas, Michael, Baechmann, Sibylle, Altendorf-Hofmann, Annelore, Remold, Anna, Quietzsch, Detlef, Clemens, Michael R, Bentz, Martin, Geissler, Michael, Lambertz, Helmut, Kruger, Stephan, Kirchner, Thomas, Heinemann, Volker, Boeck, Stefan
Publicado no Br J Cancer (2016)

pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104

Por Ormanns, Steffen, Siveke, Jens T, Heinemann, Volker, Haas, Michael, Sipos, Bence, Schlitter, Anna Melissa, Esposito, Irene, Jung, Andreas, Laubender, Rüdiger P, Kruger, Stephan, Vehling-Kaiser, Ursula, Winkelmann, Cornelia, Fischer von Weikersthal, Ludwig, Clemens, Michael R, Gauler, Thomas C, Märten, Angela, Geissler, Michael, Greten, Tim F, Kirchner, Thomas, Boeck, Stefan
Publicado em 2014